Geron Corporation

UCI embryonic stem cell therapy restores walking ability in rats with neck injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries – a finding that could expand the clinical trial to include people with cervical damage. In January, the U.S. Food & Drug Admin ... more

Pharmexa again prevails against Geron in patent appeal

In May 2004 the US biotech company Geron filed an opposition against Pharmexa's issued European patent (EP1093381) covering the telomerase vaccine GV1001. In 2005, the Opposition Division of the European Patent Office refused to grant Geron's request for invalidation of the issued patent, b ... more

Studies confirm proof-of-principle for Geron's Human Embryonic Stem Cell (HESC) derived hepatocytes

Geron Corporation announced that it has developed standardized hepatocytes from human embryonic stem cells (hESCs) that can model human hepatic drug metabolism. Published in Cloning and Stem Cells (Vol. 9, No. 1, 51-62), a paper written by Geron's scientific collaborators at the Roslin Ins ... more

Geron Corporation

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple ... more